The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Clovis Oncology (Inst); CureVac (Inst); Eisai (Inst); Genomic Health (Inst); Immunomedics (Inst); Janssen-Cilag (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Tesaro (Inst)
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Celgene; CureVac; Eisai; Genomic Health; Immunomedics (Inst); Janssen-Cilag; Novartis; Pfizer; Roche (Inst); Tesaro; Vaccibody (Inst)
Research Funding - AstraZeneca; Clovis Oncology; Eisai; MSD Oncology; Novartis; Roche/Genentech; Tesaro; Vaccibody
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; PharmaMar; Roche
Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Biothera; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; ERYTECH Pharma; GlaxoSmithKline; Leuko; Lilly; Merck Sharp & Dohme; Merus; Polyphor; Roche; Seagen; SERVIER
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Novartis; Pfizer; Roche
 
Geraldine Gebhart
Consulting or Advisory Role - Roche (I)
Research Funding - Roche (Inst)
 
Manuel Ruiz Borrego
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche
 
Agostina Stradella
Consulting or Advisory Role - Roche
Speakers' Bureau - Eisai; Roche
Expert Testimony - Eisai; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Begoña Bermejo
Consulting or Advisory Role - Genentech; MSD
Speakers' Bureau - Genentech
Travel, Accommodations, Expenses - Pfizer
 
Santiago Escrivá
Consulting or Advisory Role - Pierre Fabre; Roche
Speakers' Bureau - Eisai; Pierre Fabre; Roche
Research Funding - Roche (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Pierre Fabre; Roche
 
Lourdes Calvo Martínez
No Relationships to Disclose
 
Nuria Ribelles
Research Funding - Pfizer (Inst)
 
Noelia Martinez
No Relationships to Disclose
 
Cinta Albacar
No Relationships to Disclose
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Amgen; Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Florence Dalenc
No Relationships to Disclose
 
Kerrou Khaldoun
No Relationships to Disclose
 
Peter Schmid
Employment - Genentech (I); Roche (I)
Honoraria - AstraZeneca; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
Marco Colleoni
Honoraria - Novartis
 
Frederik Marmé
No Relationships to Disclose
 
Noemia Afonso
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche
 
Miguel Sampayo-Cordero
Honoraria - MedSIR; Nestle Health Science; Syntax for Science
Consulting or Advisory Role - MedSIR; Nestle Health Science; Syntax for Science
Speakers' Bureau - MedSIR; Roche; Syntax for Science
Research Funding - MedSIR; Roche; Syntax for Science
Travel, Accommodations, Expenses - MedSIR; Roche; Syntax for Science
 
José Manuel Pérez-García
Consulting or Advisory Role - Lilly; Roche
Travel, Accommodations, Expenses - Roche
 
Antonio Llombart-Cussac
Leadership - Celgene; Eisai; Lilly; MSD; Novartis; Pfizer; Roche
Stock and Other Ownership Interests - Initia-Research; MedSIR
Consulting or Advisory Role - Genomic Health; GlaxoSmithKline; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
Speakers' Bureau - AstraZeneca; Lilly; MSD
Research Funding - Agendia (Inst); Foundation Medicine (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Novartis; Pfizer; Roche